Source: CureToday articles
The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.
Recent Content
- Study Links PAK5 to Poor Outcomes and Drug Resistance in HER2-Positive Breast Cancer
- The Burst of Spring: Reflection for Those Living with Cancer
- Introducing Obecabtagene Autoleucel: A New Chapter in ALL Treatment
- “We’ve Got to Get This Right From the Start”: Expert Discusses MDPNP Impacts on Pharmacies
- Full COVID-19 mRNA Vaccination Course Induces Long-Term Antibody, Memory B-Cell Response
- A Pharmacist’s Guide to Lung Cancer and Its Key Treatments
- Ivonescimab Plus Chemo May Slow Advanced NSCLC Progression
- FDA Grants Breakthrough Status to CAR-T Therapy for Pediatric Brain Tumor
- NCCN Flash Update: Guideline Update for Squamous Cell Carcinoma in Version 3.2025
- States Grant Prescribing Authority to Psychologists